Dow Up0.59% Nasdaq Up0.75%

More On QIA.DE

Quotes

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Qiagen NV (QIA.DE)

-XETRA
18.11 Down 0.02(0.11%) 11:35AM EDT
ProfileGet Profile for:
Qiagen NV
Spoorstraat 50
Venlo, 5911 KJ
Netherlands - Map
Phone: 31 77 320 8400
Website: http://www.qiagen.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Medical Laboratories & Research
Full Time Employees:4,200

Business Summary 

QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. It offers approximately 500 core consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform raw biological samples into molecular information. The company’s consumable products are used for plasmid deoxyribonucleic acid (DNA) purification, and ribonucleic acid purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. The company sells the digene HC2 HPV Test, a test for high-risk strains of the human papillomavirus. It also offers co-development services for companion diagnostics, technology licensing and patent sales services, and custom services, including whole genome amplification, DNA sequencing, and non-cGMP DNA production on a contract basis. In addition, the company provides instrumentation systems that automate the use of sample and assay technologies into solutions for a range of laboratory needs enabling customers to perform nucleic acid sample preparation, assay setup, and target detection, as well as workflow solutions. Its automated systems include QIAsymphony, a modular system; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform; QIAcube, a sample processing instrument; QIAxcel for nucleic acid separation; and ESE-Quant Tube Scanners, an optical measurement device. The company serves molecular diagnostics laboratories; applied testing customers; pharmaceutical research and development groups, and academic researchers. It has a collaboration agreement with AstraZeneca PLC for the co-development and commercialization of a liquid biopsy-based companion diagnostic. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Qiagen NV

Key Executives 
 PayExercised
Mr. Peer M. Schatz , 49
Chairman of Management Board, Chief Exec. Officer and Managing Director
1.58M0.00
Dr. Metin Colpan Ph.D., 59
Co-Founder, Sr. Technology Advisor, Supervisory Director and Member of Selection & Appointment (Nomination) Committee
54.00K0.00
Mr. Roland Sackers , 46
Chief Financial Officer, Managing Director and Member of Management Board
798.00K0.00
Mr. Douglas Liu ,
Sr. VP of Global Operations
N/AN/A
Mr. John Gilardi ,
VP of Corp. Communications & Investor Relations
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in EUR.